Evan Thompson is a founder and COO of Abcuro, a company developing biologic therapeutics for autoimmunity and oncology. Prior to Abcuro, he founded and led a therapeutic nucleic acid company in Paris, and has consulted with both companies and investors in the healthcare and industrial biotechnology space. Previously, he was an analyst at RA Capital Management, evaluating public and private market investments in health care, focusing on gene and cell therapy, oncology, and infectious and rare diseases. He received a Ph.D. in Biology from Johns Hopkins University and postdoctoral training in computational biology at NCBI and synthetic biology at MIT.

​

LinkedIn